TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT01288755

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: TMC278
Description: One 25 mg tablet, once daily, for 11 days (TrtA and C)

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Raltegravir
Description: One 400 mg tablet, twice daily, for 4 days (Trt B) and for 11 days (TrtC)
Study: NCT03006146

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Sargramostim
Description: Participants will receive a single administration of inhaled sargramostim (either 125 mcg or 250 mcg dose)
Study: NCT03016312

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Atezolizumab
Description: Atezolizumab will be administered at a fixed dose of 1200 milligrams (mg), intravenous (IV) infusion on Day 1 of each 21-day cycle.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Enzalutamide
Description: Enzalutamide capsules will be administered orally at a dose of 160 mg daily.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Enzalutamide
Description: Enzalutamide capsules will be administered orally at a dose of 160 mg daily.
Study: NCT03036410

Intervention type: DEVICE
Group type: OTHER
Intervention: standard telephone setting
Description: without streaming function

Intervention type: DEVICE
Group type: OTHER
Intervention: standard telephone setting
Description: without streaming function

Intervention type: DEVICE
Group type: OTHER
Intervention: standard telephone setting
Description: without streaming function

Intervention type: DEVICE
Group type: OTHER
Intervention: standard telephone setting
Description: without streaming function

Intervention type: DEVICE
Group type: OTHER
Intervention: DECT
Description: cordless telephone (streaming to both hearing devices)

Intervention type: DEVICE
Group type: OTHER
Intervention: DECT
Description: cordless telephone (streaming to both hearing devices)

Intervention type: DEVICE
Group type: OTHER
Intervention: DECT
Description: cordless telephone (streaming to both hearing devices)

Intervention type: DEVICE
Group type: OTHER
Intervention: DECT
Description: cordless telephone (streaming to both hearing devices)

Intervention type: DEVICE
Group type: OTHER
Intervention: EasyCall
Description: accessories for Bluetooth capable mobile telephones (streaming to both hearing devices)

Intervention type: DEVICE
Group type: OTHER
Intervention: EasyCall
Description: accessories for Bluetooth capable mobile telephones (streaming to both hearing devices)

Intervention type: DEVICE
Group type: OTHER
Intervention: EasyCall
Description: accessories for Bluetooth capable mobile telephones (streaming to both hearing devices)

Intervention type: DEVICE
Group type: OTHER
Intervention: EasyCall
Description: accessories for Bluetooth capable mobile telephones (streaming to both hearing devices)

Intervention type: DEVICE
Group type: OTHER
Intervention: DuoPhone
Description: streaming function, which provides the speech signal to both ears

Intervention type: DEVICE
Group type: OTHER
Intervention: DuoPhone
Description: streaming function, which provides the speech signal to both ears

Intervention type: DEVICE
Group type: OTHER
Intervention: DuoPhone
Description: streaming function, which provides the speech signal to both ears
Study: NCT01089686

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Venoplasty
Description: Venous access is obtained from the groin through the femoral vein. The catheter will be advanced into the veins in the neck and chest. Angiographic images will be taken of the extracranial venous system as well as the azygous vein. These images will be used to confirm CCSVI. Venoplasty is performed by inserting an additional catheter with a balloon at the tip. The balloon will be inflated to open the vessel. Once dilation of the vessel is confirmed, the venous sheath will be removed and manual compression applied to the groin access.

Intervention type: PROCEDURE
Group type: SHAM_COMPARATOR
Intervention: Sham procedure (non-treatment)
Description: Venous access is obtained from the groin through the femoral vein. The catheter will be advanced into the veins in the neck and chest. Angiographic images will be taken of the extracranial venous system as well as the azygous vein. These images will be used to confirm CCSVI. Since the patient has been randomized to the non-treatment arm of the trial, the procedure will end without venoplasty. After completion of the diagnostic venogram, the venous sheath will be removed and manual compression applied to the groin access.
Study: NCT03880292

Intervention type: PROCEDURE
Group type: OTHER
Intervention: Document intraoperative Maneuvers
Description: Monitoring procedure during surgery
Study: NCT02632292

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Absorb GT1
Description: Bioresorbable vascular scaffold

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Promus
Description: Everolimus-eluting stent
Study: NCT02721667

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Telemonitoring
Description: Secure, wireless transmission of home blood pressure measurements that are summarized in a secure health portal for healthcare providers use for clinical management decisions, including calculation of mean BP and graphing of temporal trends.

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Case Management
Description: Case managers work collaboratively with patients and physicians to optimize health behaviours, monitor risk factors, implement therapeutic adjustments, encourage adherence, and coordinate follow-up care.
Study: NCT05729971

Intervention type: PROCEDURE
Intervention: nasogastric tube
Description: The intervention consists in removing or not the nasogastric tube at the end of the surgery.
Study: NCT03268525

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Marcaine 0.5 % Injectable Solution
Description: Local infiltration by Marcaine 0.5% Injectable Solution prior to incision

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Sodium Chloride 0.9%
Description: Local infiltration by Sodium Chloride 0.9% prior to incision
Study: NCT04247087

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: phytomenadione
Description: phytomenadione 10 mg (1 vial in the venous line of the extracorporeal hemodialysis circuit) post hemodialysis 3 times a week for 12 months

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: placebo solution
Description: 1 vial of placebo solution (solution for injection in the venous line of the extracorporeal hemodialysis circuit) post hemodialysis 3 times a week for 12 months
Study: NCT02750982

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Laughter Therapy
Description: Laughter Therapy (LT) involves simple exercises using playfulness, eye contact and chanting in forms of laughter. LT will be taught by a certified LT instructor in a group session. There will be 8 sessions per group with each session attended by 8-12 participants and lasting 60 minutes
Study: NCT03568396

Intervention type: DEVICE
Intervention: Pupillometer
Description: Measurement of pupil diameter and reactivity in response to a standard noxious stimulus in cardiac surgery during extracorporeal circulation period.
Study: NCT01046773

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Cholecalciferol
Description: Children less than 35 kg will receive 2,000 IU oral cholecalciferol daily for 6 months.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Cholecalciferol
Description: Children 35 kg or greater will receive 4,000 IU oral cholecalciferol daily for 6 months.
Study: NCT04081623

Intervention type: DEVICE
Intervention: Raydiant Oximetry Sensing System
Description: The investigational device is used to record fetal pulse signals.

Intervention type: DEVICE
Intervention: Raydiant Oximetry Sensing System
Description: The investigational device is used to record fetal pulse signals.
Study: NCT01375231

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Measured Resection of patellofemoral joint
Description: The goal is to remove an amount of bone from the patella so that when reconstructed, the composite thickness of the entire prosthetic patellofemoral joint is recreated

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Measured resection of patella
Description: The thickness of the anterior condyle is not considered in this measurement. The goal is to restore the composite thickness of the patella only.
Study: NCT02960750

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: A workplace sit less and move more web-based program for Spanish office employees
Description: W@WS encourages office employees to progressively 'sit less and move more' during workdays over 19 weeks. During the first 8 weeks (ramping phase), tips are provided every two weeks to break occupational sitting time through incidental movement during work tasks, introduce short walks (5-10 minutes) during morning/afternoon work breaks and/or commuting time, introduce longer walks at lunchtime and achieve at least 10,000 daily steps as well as increase walking intensity. During weeks 9 to 19, W@WS provides automated guidance with periodic emails encouraging behaviors achieved in the previous phase. Ecological support strategies such as logging daily step counts into a personal account and receiving visual feedback on the achievement of goals are also provided

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Active Comparison group
Description: The Active Comparison group maintained habitual behavior. The A-CG was given a pedometer and a paper diary to register daily step counts and self-reported sitting time throughout the intervention.
Study: NCT02645227

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Open flap debridement (OFD)
Description: Oral prophylaxis followed by OFD for treating bone defect

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: OFD with Platelet rich fibrin (PRF)
Description: Oral prophylaxis followed by OFD with PRF placement into the bone defect

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: OFD with PRF and 1.2% Rosuvastatin
Description: Oral prophylaxis followed by OFD with PRF and 1.2% Rosuvastatin placement into the bone defect
Study: NCT02224690

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: GWP42003-P 20 mg/kg/day Dose
Description: GWP42003-P was presented as an oral solution containing 100 mg/milliliter (mL) cannabidiol (CBD) in the excipients sesame oil and anhydrous ethanol (79 mg/mL) with added sweetener (0.5 mg/mL sucralose) and strawberry flavoring (0.2 mg/mL).

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo was presented as an oral solution containing 0 mg/mL CBD in the excipients sesame oil and anhydrous ethanol (79 mg/mL) with added sweetener (0.5 mg/mL sucralose) and strawberry flavoring (0.2 mg/mL).
Study: NCT04638595

Intervention type: OTHER
Intervention: Observation
Description: This project seeks to recruit 25 male and 25 female typically developing children between the ages of 3 and 18 years of age. Non-invasive measurements of movement patterns will be collected during common activities of daily living over a single data collection session.
Study: NCT01383460

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Granulocyte Colony-stimulating Factor (G-CSF) and Erythropoetin (EPO)
Description: G-CSF (in prefilled syringe) at a dose of 5 µg/kg s/c at days 1, 2, 3, 4, 5 and then every 3rd day till day 28 (total 12 doses), along with Darbopoetin alpha 100 mcg/ week (in prefilled syringe) for 4 weeks (total 4 doses).

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo 1 (in prefilled syringe) s/c at days 1, 2, 3, 4, 5 and then every 3rd day till day 28 (total 12 doses), along with Placebo 2 every week (in prefilled syringe) for 4 weeks (total 4 doses).
Study: NCT01911611

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: RO6870868
Description: Single ascending doses

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: placebo
Description: Single ascending doses
Study: NCT02876822

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Vitamin D
Study: NCT01590979

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Ranolazine
Description: 1000mg, two times a day, 12 hour intervals

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: two times a day, 12 hour intervals
Study: NCT03148535

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Lithium Carbonate
Description: bipolar depression recieve lithium Carbonate treatment
Study: NCT00950274

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: CD133+ autologous bone marrow stem cell
Description: Intramyocardial injection of 5 mL CD133+ cells (0.5-5x10e6 cells) suspended in physiological saline + 10% autologous serum intramyocardially during CABG surgery
Study: NCT03148535

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: lithium carbonate combined with SSRI antidepressant treatment
Description: lithium carbonate combined with SSRI antidepressant treatment
Study: NCT01855412

Intervention type: OTHER
Intervention: PAD endovascular treatments
Description: All FDA-cleared endovascular PAD treatments

Intervention type: OTHER
Intervention: PAD endovascular treatments
Description: All FDA-cleared endovascular PAD treatments

Intervention type: OTHER
Intervention: PAD endovascular treatments
Description: All FDA-cleared endovascular PAD treatments
Study: NCT01329263

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Menthol to non-menthol
Description: Switch from smoking menthol to non-menthol cigarettes.
Study: NCT00950274

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Intramyocardial injection of 5 mL of physiological saline + 10% autologous serum intramyocardially during CABG surgery
Study: NCT00851838

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: L-Carnitine
Description: Instillation of glucose-based (1.5 or 2.5 w/v) PD solution containing L-carnitine during the nocturnal exchange in APD treated patients. L-Carnitine (0.1% w/v) is present only in the first 5 Liter APD bag. PD solutions are instilled for 5 days.
Study: NCT00665665

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: NNC 0070-0002-0182
Description: 4mg initial dose (12 subjects active; 3 subjects placebo); 2mg weekly maintenance dose; for s.c. injection 20mg/vial

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: placebo
Description: Placebo for s.c. injection

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: placebo
Description: Placebo for s.c. injection

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: placebo
Description: Placebo for s.c. injection

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: placebo
Description: Placebo for s.c. injection

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: NNC 0070-0002-0182
Description: 12mg initial dose (12 subjects active; 3 subjects placebo); 6mg weekly maintenance dose; for s.c. injection 20mg/vial

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: NNC 0070-0002-0182
Description: 32mg initial dose (12 subjects active; 3 subjects placebo); 16mg weekly maintenance dose; for s.c. injection 20mg/vial

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: NNC 0070-0002-0182
Description: 60mg initial dose (12 subjects active; 3 subjects placebo); 30mg weekly maintenance dose; for s.c. injection 20mg/vial
Study: NCT01631435

Intervention type: OTHER
Group type: OTHER
Intervention: Pillcam colon capsule and PillCam™ Prep Procedure
Description: PillCam® Crhon capsule preparation will include a clear liquid diet and administration of a purgative sulfate-free polyethylene glycol electrolyte lavage (SF-ELS) solution (e.g. Nulytely) divided into two doses: the first dose on the evening before the exam and the 2nd dose on the morning of the exam day.

Intervention type: DEVICE
Group type: OTHER
Intervention: Ileocolonoscopy
Description: Conventional ileocolonoscopy Examination (same day or within 24 hours)of CE procedure~• Ileocolonoscopy with intubation of terminal ileum
Study: NCT02122679

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Tranexamic Acid

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: placebo
Study: NCT03007966

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Ilioinguinal / Iliohypogastric Block
Description: Patients randomized to this arm will receive 25cc's of Bupivacaine 0.25% + Epinephrine 1:200k + Clonidine 1.66mcg/cc administered via an ultrasound guided ilioinguinal / iliohypogastric block technique.

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Quadratus Lumborum Block
Description: Patients randomized to this arm will receive 25cc's of Bupivacaine 0.25% + Epinephrine 1:200k + Clonidine 1.66mcg/cc administered via an ultrasound guided quadratus lumborum block technique.
Study: NCT01266681

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: amiodarone
Description: Visit One:. Once consent is given patarticipants will be randomised into either group and instructed and prescribed the drug as appropriate.~Visit Two: Patients will attend for routine cardioversion. This is performed by an experienced CCU nurse as per normal protocol. Patients will also undergo an ECG, and fill in symptom and quality of life (QoL) questionnaires.~Visit Three: Patients will attend a routine outpatient appointment 6 weeks post cardioversion. They will undergo ECG and fill in symptom and QoL questionnaires~Visit Four: Participants will attend at 12 weeks for ECG, symptom and QoL questionnaires~Visit Five: Participants will attend at 24 weeks for ECG, symptom and QoL questionnaires~Visit Six: Participants will attend at 36 weeks for ECG, symptom and QoL questionnaires~Visit Seven: Participants will attend at 52 weeks for ECG, symptom and QoL questionnaires. Participants will then be followed up as per protocol by their consultant cardiologist.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Dronedarone
Description: Visit One: patarticipants will be randomised into either group and instructed and prescribed the drug as appropriate.~Visit Two: Patients will attend for routine cardioversion. This is performed by an experienced CCU nurse as per normal protocol. Patients will also undergo an ECG, and fill in symptom and quality of life (QoL) questionnaires.~Visit Three: Patients will attend a routine outpatient appointment 6 weeks post cardioversion. They will undergo ECG and fill in symptom and QoL questionnaires~Visit Four: Participants will attend at 12 weeks for ECG, symptom and QoL questionnaires~Visit Five: Participants will attend at 24 weeks for ECG, symptom and QoL questionnaires~Visit Six: Participants will attend at 36 weeks for ECG, symptom and QoL questionnaires~Visit Seven: Participants will attend at 52 weeks for ECG, symptom and QoL questionnaires. Participants will then be followed up as per protocol by their consultant cardiologist.
Study: NCT00003453

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Antineoplaston therapy (Atengenal + Astugenal)
Description: Patients with Stage IV Adrenal Gland Cancer will receive Antineoplaston therapy (Atengenal + Astugenal).~The daily doses of A10 and AS2-1 are divided into six infusions, which are given at 4-hourly intervals. Each infusion starts with infusion of A10 and is immediately followed by infusion of AS2-1.
Study: NCT01818583

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Potassium chloride

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Glucose 50 MG/ML
Study: NCT02129270

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Lidocaine HCl 2% .
Description: comparison of different dosages of drug

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Lidocaine HCl 1%
Description: comparison of different dosages of drug
Study: NCT02299180

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: ACP
Study: NCT04129216

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Tamoxifen Citrate
Description: 10mg administered daily. Patients take this drug for 2-6 weeks

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Letrozole
Description: 2.5mg is administered daily. Patients take this drug for 2-6 weeks

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Exemestane
Description: 25mg is administered daily. Patients take this drug for 2-6 weeks.

Intervention type: DIAGNOSTIC_TEST
Group type: EXPERIMENTAL
Intervention: Blueprint
Description: studies the genomics of the tumor and tumor behavior

Intervention type: DIAGNOSTIC_TEST
Group type: EXPERIMENTAL
Intervention: Blueprint
Description: studies the genomics of the tumor and tumor behavior

Intervention type: DIAGNOSTIC_TEST
Group type: EXPERIMENTAL
Intervention: Blueprint
Description: studies the genomics of the tumor and tumor behavior

Intervention type: DIAGNOSTIC_TEST
Group type: EXPERIMENTAL
Intervention: Mammaprint
Description: studies the genomics of the tumor

Intervention type: DIAGNOSTIC_TEST
Group type: EXPERIMENTAL
Intervention: Mammaprint
Description: studies the genomics of the tumor
Study: NCT03007966

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Bupivacaine 0.25%
Description: Administered as part of the local anesthetic mixture

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Bupivacaine 0.25%
Description: Administered as part of the local anesthetic mixture

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Epinephrine 1:200k
Description: Administered as part of the local anesthetic mixture

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Epinephrine 1:200k
Description: Administered as part of the local anesthetic mixture
Study: NCT04129216

Intervention type: DIAGNOSTIC_TEST
Group type: EXPERIMENTAL
Intervention: Mammaprint
Description: studies the genomics of the tumor
Study: NCT03007966

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Clonidine 1.66mcg/cc
Description: Administered as part of the local anesthetic mixture

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Clonidine 1.66mcg/cc
Description: Administered as part of the local anesthetic mixture
Study: NCT02848287

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: normal saline
Description: 1\*2 gauze is soaked with 5 cc of 0.9 % normal saline, applied in tonsillar fossae for 3 min, then removed.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ropivacaine
Description: 1\*2 gauze is soaked with 5 cc of 0.75% ropivacaine, applied in tonsillar fossae for 3 min, then removed.
Study: NCT00371683

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Enoxaparin + Placebo
Description: Syringes + tablets, Subcutaneous + Oral, 30mg, twice daily, 12 day treatment period
Study: NCT02372578

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ASP3662
Description: oral

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: pregabalin
Description: oral

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ASP3662 placebo
Description: oral

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: ASP3662 placebo
Description: oral

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: ASP3662 placebo
Description: oral
Study: NCT00371683

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Apixaban + Placebo
Description: Tablet + Syringes, Oral + subcutaneous, 2.5 mg, twice daily, 12 day treatment period